Evidence map›Paper›PMID 36851662›Full record

ArticleViruses2023

Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19.

Muneerah Smith, Gaurav Kwatra, Alane Izu, Andrew Nel, Clare Cutland, Khatja Ahmed, Vicky Baillie, Shaun Barnabas, Qasim Bhorat, Carmen Briner and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Muneerah SmithDepartment of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.ORCID 0000-0002-1516-3270
Gaurav KwatraSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit (Wits-VIDA), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2050, South Africa.
Alane IzuSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit (Wits-VIDA), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2050, South Africa.
Andrew NelDepartment of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
Clare CutlandAfrican Leadership in Vaccinology Expertise (ALIVE), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2050, South Africa.ORCID 0000-0001-8250-8307
Khatja AhmedSetshaba Research Centre, Tshwane 0182, South Africa.
Vicky BaillieSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit (Wits-VIDA), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2050, South Africa.
Shaun BarnabasFamily Centre for Research with Ubuntu, Department of Paediatrics, Stellenbosch University, Cape Town 7600, South Africa.
Qasim BhoratSoweto Clinical Trials Centre, Soweto 6201, South Africa.ORCID 0000-0002-4102-8750
Carmen BrinerPerinatal HIV Research Unit, Faculty of Health Science, University of the Witwatersrand, Johannesburg 2050, South Africa.
Erica LazarusPerinatal HIV Research Unit, Faculty of Health Science, University of the Witwatersrand, Johannesburg 2050, South Africa.
Keertan DhedaCentre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute, University of Cape Town, Cape Town 7925, South Africa.
Lee FairlieWits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2050, South Africa.
Anthonet KoenSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit (Wits-VIDA), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2050, South Africa.
Shabir MadhiSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit (Wits-VIDA), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2050, South Africa.ORCID 0000-0002-7629-0636
Jonathan M BlackburnDepartment of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.ORCID 0000-0001-8988-9595
South African Medical Research Council · ZAUniversity of Cape Town · ZAUniversity of the Witwatersrand · ZASetshaba Research Centre · ZASoweto CTC · ZAStellenbosch University · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccines against SARS-CoV-2 have been pivotal in overcoming the COVID-19 pandemic yet understanding the subsequent outcomes and immunological effects remain crucial, especially for at-risk groups e.g., people living with human immunodeficiency virus (HIV) (PLWH). In this study we report the longitudinal IgA and IgG antibody titers, as well as antibody-mediated angiotensin converting enzyme 2 (ACE2) binding blockade, against the SARS-CoV-2 spike (S) proteins after 1 and 2 doses of the ChAdOx1 nCoV-19 vaccine in a population of Black PLWH. Here, we report that PLWH (N = 103) did not produce an anti-S IgA response after infection or vaccination, however, anti-S IgG was detected in response to vaccination and infection, with the highest level detected for infected vaccinated participants. The anti-IgG and ACE2 blockade assays revealed that both vaccination and infection resulted in IgG production, however, only vaccination resulted in a moderate increase in ACE2 binding blockade to the ancestral S protein. Vaccination with a previous infection results in the greatest anti-S IgG and ACE2 blockade for the ancestral S protein. In conclusion, PLWH produce an anti-S IgG response to the ChAdOx1 nCoV-19 vaccine and/or infection, and ChAdOx1 nCoV-19 vaccination with a previous infection produced more neutralizing antibodies than vaccination alone.

Indexed as

Angiotensin-Converting Enzyme 2COVID-19Antibodies, BlockingAntibodies, NeutralizingChAdOx1 nCoV-19COVID-19 VaccinesHumansImmunoglobulin AImmunoglobulin GPandemicsSARS-CoV-2Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Antibodies, BlockingAntibodies, NeutralizingChAdOx1 nCoV-19COVID-19 VaccinesImmunoglobulin AImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19HIVIgAIgGneutralizationSARS-CoV-2 spike proteinvaccine

Identifiers

PMID36851662
PMCPMC9965153
OpenAlexW4319317816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.